Opinion|Videos|August 26, 2024
Advancements in MIST for BPH: Options, Guidelines, and Patient-Centered Decision-Making
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you please provide a high-level overview of the following available minimally invasive surgical therapies (MIST) options for benign prostate dysplasia (BPH) and how they work?
- Laser therapy
- Prostatic urethral lift procedure
- Water vapor thermal therapy
- Robotic waterjet treatment
- Photoselective vaporization of the prostate
- Any other novel therapeutic options
- How has the emergence of MIST impacted the management of patients with BPH?
- What are the current American
- Which patients make good candidates for MIST options?
- When/why do you consider a MIST vs surgery (patient prognosis, patient preference, comorbidities)?
- What role does patient preference play in choosing medication vs surgery vs a MIST? Please speak to the importance of shared decision-making.
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5